This observation suggested that deletion mutations of PBRM1 in tumor cells do not affect the proliferative capacity of colorectal cancer cells in vitro; however, they can enhance the therapeutic sensitivity of colorectal cancer cells to PD-1 immunotherapy. Here, PBRM1 is linked to neoplasm.